Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simvastatin to Prevent Liver Cancer in Liver Cirrhosis
NCT02968810Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2017
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised trial in hepatocellular carcinoma (HCC) comparing Group I (simvastatin) with Group II (placebo) (2 arms). Primary endpoint: Change in Serum Alpha-Fetoprotein L3 Percent at 6 months. Started Jun 2017; status: completed.
02
Drugs
simvastatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02968810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02968810.